1. Home
  2. WVE vs EVO Comparison

WVE vs EVO Comparison

Compare WVE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • EVO
  • Stock Information
  • Founded
  • WVE 2012
  • EVO 1993
  • Country
  • WVE Singapore
  • EVO Germany
  • Employees
  • WVE N/A
  • EVO N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • WVE Health Care
  • EVO Health Care
  • Exchange
  • WVE Nasdaq
  • EVO Nasdaq
  • Market Cap
  • WVE 1.8B
  • EVO 1.6B
  • IPO Year
  • WVE 2015
  • EVO 2021
  • Fundamental
  • Price
  • WVE $11.13
  • EVO $4.44
  • Analyst Decision
  • WVE Strong Buy
  • EVO Buy
  • Analyst Count
  • WVE 10
  • EVO 2
  • Target Price
  • WVE $21.60
  • EVO $5.90
  • AVG Volume (30 Days)
  • WVE 734.1K
  • EVO 46.1K
  • Earning Date
  • WVE 03-05-2025
  • EVO 11-06-2024
  • Dividend Yield
  • WVE N/A
  • EVO N/A
  • EPS Growth
  • WVE N/A
  • EVO N/A
  • EPS
  • WVE N/A
  • EVO N/A
  • Revenue
  • WVE $53,610,000.00
  • EVO $866,665,179.00
  • Revenue This Year
  • WVE N/A
  • EVO $3.84
  • Revenue Next Year
  • WVE $48.58
  • EVO $10.94
  • P/E Ratio
  • WVE N/A
  • EVO N/A
  • Revenue Growth
  • WVE N/A
  • EVO N/A
  • 52 Week Low
  • WVE $4.01
  • EVO $2.85
  • 52 Week High
  • WVE $16.74
  • EVO $7.98
  • Technical
  • Relative Strength Index (RSI)
  • WVE 44.53
  • EVO 49.82
  • Support Level
  • WVE $10.79
  • EVO $4.40
  • Resistance Level
  • WVE $11.78
  • EVO $4.49
  • Average True Range (ATR)
  • WVE 0.69
  • EVO 0.10
  • MACD
  • WVE 0.05
  • EVO -0.00
  • Stochastic Oscillator
  • WVE 43.95
  • EVO 38.46

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: